HUMAN NEUROPEPTIDE-Y Y(1)-RECEPTOR ANTISENSE OLIGODEOXYNUCLEOTIDE SPECIFICALLY INHIBITS NEUROPEPTIDE Y-EVOKED VASOCONSTRICTION

被引:29
|
作者
ERLINGE, D
EDVINSSON, L
BRUNKWALL, J
YEE, F
WAHLESTEDT, C
机构
[1] LUND UNIV,DEPT INTERNAL MED,S-22101 LUND,SWEDEN
[2] LUND UNIV,DEPT EXPTL RES,S-22101 LUND,SWEDEN
[3] CORNELL UNIV,MED CTR,COLL MED,DEPT NEUROL & NEUROSCI,DIV NEUROBIOL,NEW YORK,NY 10021
[4] LUND UNIV,MALMO GEN HOSP,DEPT SURG,S-22101 LUND,SWEDEN
关键词
NEUROPEPTIDE-Y; BLOOD VESSEL (HUMAN); ANTISENSE; NEUROPEPTIDE-Y Y(1)-RECEPTOR;
D O I
10.1016/0014-2999(93)90548-V
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This paper describes a new approach for the development of an inhibitor of the contractile responses of neuropeptide Y in human blood vessels by the use of an antisense oligodeoxynucleotide complementary to human neuropeptide Y Y1 receptor mRNA. One micromolar of an antisense 18-base oligodeoxynucleotide (hY1-AS), corresponding to the human Y1 receptor NH2-terminus, was incubated with segments of human subcutaneous arteries and veins for 48 h at 37-degrees-C. Control vessels were incubated with the corresponding sense oligodeoxynucleotide (hY1-S) or a 3-base mismatched antisense oligodeoxynucleotide (hY1-MM) or no oligodeoxynucleotide. The contractile response to neuropeptide Y was markedly attenuated in both arteries and veins after treatment with hY1-AS, but was unaffected by hY1-S or hY1-MM. The pD2 values, i.e. the potency of neuropeptide Y, did not differ in hY1-AS treated vessels, suggesting a non-competitive receptor interaction as a result of down-regulation of Y1 receptors. Responses to noradrenaline or high K+ were unaffected by hY1-AS. This study may represent a new and highly specific approach to vascular pharmacology.
引用
收藏
页码:77 / 80
页数:4
相关论文
共 50 条
  • [1] Effects of phosphorothioated neuropeptide Y Y-1-receptor antisense oligodeoxynucleotide in conscious rats and in human vessels
    Sun, XY
    Zhao, XH
    Erlinge, D
    Edvinsson, L
    Fallgren, B
    Wahlestedt, C
    Hedner, T
    BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (01) : 131 - 136
  • [2] NEUROPEPTIDE-Y AND NEUROPEPTIDE-Y RECEPTOR SUBTYPES IN BRAIN AND PERIPHERAL-TISSUES
    DUMONT, Y
    MARTEL, JC
    FOURNIER, A
    STPIERRE, S
    QUIRION, R
    PROGRESS IN NEUROBIOLOGY, 1992, 38 (02) : 125 - 167
  • [3] NEUROPEPTIDE-Y RECEPTOR SUBTYPES
    WAN, CP
    LAU, BHS
    LIFE SCIENCES, 1995, 56 (13) : 1055 - 1064
  • [4] NEUROPEPTIDE-Y RECEPTOR SUBTYPES, Y1 AND Y2
    WAHLESTEDT, C
    GRUNDEMAR, L
    HAKANSON, R
    HEILIG, M
    SHEN, GH
    ZUKOWSKAGROJEC, Z
    REIS, DJ
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 611 : 7 - 26
  • [5] NEUROPEPTIDE-Y POTENTIATES NORADRENALINE-EVOKED VASOCONSTRICTION - MODE OF ACTION
    WAHLESTEDT, C
    EDVINSSON, L
    EKBLAD, E
    HAKANSON, R
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1985, 234 (03): : 735 - 741
  • [6] CHARACTERIZATION OF THE HUMAN Y1 NEUROPEPTIDE-Y RECEPTOR EXPRESSED IN INSECT CELLS
    MUNOZ, M
    SAUTEL, M
    MARTINEZ, R
    SHEIKH, SP
    WALKER, P
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1995, 107 (01) : 77 - 86
  • [7] ACTIVATION OF NEUROPEPTIDE Y1-RECEPTOR AND NEUROPEPTIDE Y2-RECEPTOR BY SUBSTITUTED AND TRUNCATED NEUROPEPTIDE-Y ANALOGS - IDENTIFICATION OF SIGNAL EPITOPES
    GRUNDEMAR, L
    KRSTENANSKY, JL
    HAKANSON, R
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 232 (2-3) : 271 - 278
  • [8] Neuropeptide Y-evoked proliferation of retinal glial (Muller) cells
    Milenkovic, I
    Weick, M
    Wiedemann, P
    Reichenbach, A
    Bringmann, A
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2004, 242 (11) : 944 - 950
  • [9] SYNTHESIS OF RECEPTOR ANTAGONISTS OF NEUROPEPTIDE-Y
    TATEMOTO, K
    MANN, MJ
    SHIMIZU, M
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (04) : 1174 - 1178
  • [10] POTENTIATION BY NEUROPEPTIDE-Y OF VASOCONSTRICTION IN RAT RESISTANCE ARTERIES
    ANDRIANTSITOHAINA, R
    STOCLET, JC
    BRITISH JOURNAL OF PHARMACOLOGY, 1988, 95 (02) : 419 - 428